Rheumatology · Red Bank, NJ
NPI
1588665913
Since 2005
Specialty
Rheumatology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
282 Broad Street
Red Bank, NJ, 07701
Phone (732) 842-3600
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.8M
453,617 services
Medicare patients, 2024
995
Average age 74
Drug cost, 2024
$5.3M
8,413 prescriptions
Company payments, 2025
$29K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Edward C Allegra II was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 210,040 times for 76 patients. In total Edward C Allegra II billed 453,617 services in 53 codes, and Medicare paid $3.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-02-21.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 210,040 | 76 | $3.61 | $759K |
| J3262 Injection, tocilizumab, 1 mg | Office | 90,440 | 28 | $4.70 | $425K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 66,530 | 89 | $8.98 | $597K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 20,800 | 40 | $32.99 | $686K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 20,370 | 21 | $8.44 | $172K |
| J0897 Injection, denosumab, 1 mg | Office | 12,900 | 150 | $20.46 | $264K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 8,230 | 29 | $24.32 | $200K |
| J7329 Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg | Office | 3,700 | 24 | $5.66 | $21K |
| J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2,243 | 357 | $5.29 | $12K |
| J3304 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 1,874 | 18 | $13.57 | $25K |
| 96372 Injection Administration | Office | 1,213 | 338 | $12.48 | $15K |
| 96413 Chemotherapy Administration | Office | 1,135 | 192 | $116.30 | $132K |
| 96401 Chemotherapy Administration | Office | 1,066 | 78 | $65.39 | $70K |
| 99213 Office E&M - Established | Office | 1,054 | 572 | $73.05 | $77K |
| 99214 Office E&M - Established | Office | 827 | 432 | $105.45 | $87K |
By year: 2022 $3.5M for 398,666 services; 2023 $3.6M for 445,928 services; 2024 $3.8M for 453,617 services.
Medicare prescription drug claims, 2024
In 2024, the drug Edward C Allegra II prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 1,457 prescriptions and refills. In total Edward C Allegra II wrote 8,413 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 1,457 | 3,440 | 414 | $34K |
| Prednisone Generic | 754 | 994 | 222 | $4,313 |
| Hydroxychloroquine Sulfate Generic | 444 | 973 | 138 | $18K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 396 | 396 | 50 | $9,632 |
| Tramadol Hcl Generic | 335 | 335 | 65 | $1,207 |
| Allopurinol Generic | 328 | 877 | 105 | $4,353 |
| Gabapentin Generic | 314 | 474 | 81 | $2,886 |
| Oxycodone Hcl Generic | 216 | 216 | 23 | $4,423 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 210 | 210 | 37 | $5,158 |
| Celecoxib Generic | 189 | 353 | 71 | $4,978 |
| Folic Acid Generic | 174 | 449 | 57 | $1,619 |
| Diclofenac Sodium Generic | 171 | 247 | 62 | $7,112 |
| Morphine Sulfate Er Morphine Sulfate | 163 | 163 | 20 | $3,557 |
| Alprazolam Generic | 148 | 148 | 25 | $538 |
| Meloxicam Generic | 147 | 275 | 39 | $592 |
Brand drugs: - claims; generic drugs: 7,502 claims; opioid claims: 1,552.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Edward C Allegra II $29K ($29K in general payments such as food, travel and fees) from 21 companies. The largest payer was Abbvie Inc. with $19K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 46 | $19K |
| Pfizer Inc. PFE | 25 | $4,798 |
| Janssen Biotech, Inc. JNJ | 63 | $1,282 |
| Amgen Inc. AMGN | 41 | $876 |
| AstraZeneca Pharmaceuticals LP AZN | 21 | $494 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $272 |
| ANI Pharmaceuticals, Inc. ANIP | 23 | $271 |
| UCB, Inc. UCB.BR | 12 | $241 |
| E.R. Squibb & Sons, L.L.C. BMY | 18 | $216 |
| GlaxoSmithKline, LLC. GSK | 20 | $212 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.